Erythropoietin: A Candidate Neuroprotective Agent in the Treatment of Glaucoma

  title={Erythropoietin: A Candidate Neuroprotective Agent in the Treatment of Glaucoma},
  author={J. Tsai and B. Song and Li Wu and M. Forbes},
  journal={Journal of Glaucoma},
  • J. Tsai, B. Song, +1 author M. Forbes
  • Published 2007
  • Medicine
  • Journal of Glaucoma
  • Glaucoma is a progressive optic neuropathy that is the leading cause of irreversible blindness in the world. Although methods to lower intraocular pressure are the mainstay of glaucoma therapy, there are currently no available treatment modalities targeted at neuroprotection. Erythropoietin is a hematopoietic cytokine that has been shown to possess remarkable tissue-protective properties in preclinical models of neurodegeneration. As a result, there is a growing interest to explore the… CONTINUE READING
    34 Citations
    Neuroprotection in glaucoma
    • 40
    Biochemical changes and treatment in glaucoma
    • 4
    The role of inflammation in the pathogenesis of glaucoma.
    • 114
    Recent advances in pharmacotherapy of glaucoma
    • 34
    Canadian Journal of Ophthalmology Lecture: translational research advances in glaucoma neuroprotection.
    • J. Tsai
    • Medicine
    • Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
    • 2013
    • 10


    Erythropoietin as a novel neuroprotectant.
    • 110
    Erythropoietin: a candidate compound for neuroprotection in schizophrenia
    • 172
    • PDF
    Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice.
    • 146
    • PDF
    Effect of erythropoietin axotomy-induced apoptosis in rat retinal ganglion cells.
    • 186
    • PDF
    Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy.
    • 286